Overview

A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder

Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 clinical study evaluating the safety and effectiveness of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.
Phase:
Phase 2
Details
Lead Sponsor:
Sirtsei Pharmaceuticals, Inc.